Patents Assigned to Children's Medical Center Corporation
  • Publication number: 20200377459
    Abstract: The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.
    Type: Application
    Filed: March 10, 2020
    Publication date: December 3, 2020
    Applicants: President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Bruce P. Bean, Clifford J. Woolf, Jinbo Lee, Sooyeon Jo, David P. Roberson, Sebastien Talbot
  • Publication number: 20200370048
    Abstract: Embodiments herein provide specially designed synthetic BCL11A-targeting microRNAs for RNA polymerase II expression, and methods of use to treat hemoglobinopathies such as sickle cell disease or thalassemia by increasing the expression levels of fetal hemoglobin levels.
    Type: Application
    Filed: April 6, 2020
    Publication date: November 26, 2020
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Michael MILSOM, David A. WILLIAMS, Richard GREGORY
  • Publication number: 20200368017
    Abstract: A replacement heart valve device is disclosed. In some embodiments, the device includes a frame coupled to one or more leaflets that are moveable between open and closed configurations. In some embodiments, the frame comprises at least two frame sections that join at a pair of commissural posts. In some embodiments, the device may be geometrically accommodating to adapt to different vasculature shapes and sizes and/or to be able to change size while implanted within a growing patient.
    Type: Application
    Filed: November 16, 2018
    Publication date: November 26, 2020
    Applicants: Children's Medical Center Corporation, President and Fellows of Harvard College, Massachusetts Institute of Technology
    Inventors: Sophie-Charlotte Hofferberth, Pedro J. del Nido, Elazer R. Edelman, Peter E. Hammer, Christopher Payne
  • Patent number: 10842753
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: November 24, 2020
    Assignees: Massachusetts Institute of Technology, The Children's Medical Center Corporation
    Inventors: Arturo J. Vegas, Minglin Ma, Kaitlin M. Bratlie, Daniel G. Anderson, Robert S. Langer
  • Patent number: 10844118
    Abstract: The methods, compositions, and assays described herein are based, in part, on the discovery that CD1a mediates inflammation related to certain conditions such as urushiol exposure, psoriasis and other inflammatory skin diseases. One aspect provided herein relates to a method for treating or preventing an inflammatory skin disease, the method comprising: administering a therapeutically effective amount of an inhibitor of CD 1a to a subject having an inflammatory skin disease, thereby treating or preventing the inflammatory skin diseases.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: November 24, 2020
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Florian E. Winau, Ji Hyung Kim
  • Patent number: 10842914
    Abstract: Methods for preparing and using collagen extracts and collagen scaffolds are provided. Additionally methods and related kits for the repair of articular tissue using the collagen material are provided.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: November 24, 2020
    Assignee: The Children's Medical Center Corporation
    Inventor: Martha M. Murray
  • Patent number: 10842460
    Abstract: A system or method for improving quality in projection and tomographic x-ray, which includes a depth sensing device to measure a depth of at least one body part of a patient from the depth sensing device and a control unit to calculate a thickness and/or circumference of the body part using the depth information. The calculated thickness and circumference information is used to determine an optimal level of x-ray exposure for the body part. The system or method also includes a camera to identify the body part that needs to be examined and to detect any motion of the identified body part.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: November 24, 2020
    Assignees: WASHINGTON UNIVERSITY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Steven Don, Robert MacDougall, William Clayton
  • Publication number: 20200360135
    Abstract: A replacement heart valve device is disclosed. In some embodiments, the device includes a frame coupled to one or more leaflets that are moveable between open and closed configurations. In some embodiments, the frame comprises at least two frame sections that join at a pair of commissural posts. In some embodiments, the device may be geometrically accommodating to adapt to different vasculature shapes and sizes and/or to be able to change size while implanted within a growing patient.
    Type: Application
    Filed: June 2, 2020
    Publication date: November 19, 2020
    Applicants: Children's Medical Center Corporation, President and Fellows of Harvard College, Massachusetts Institute of Technology
    Inventors: Sophie-Charlotte Hofferberth, Pedro J. del Nido, Elazer R. Edelman, Peter E. Hammer, Christopher Payne
  • Publication number: 20200362308
    Abstract: Described herein are methods for inducing HSC specification in a cell. Aspects of the invention relate to contacting a cell with a Runx1-CBF? inhibitor for a specified period of time, and then removing the inhibitor from the cell. In some embodiments of any of the aspects, HSC specificity is maintained long-term.
    Type: Application
    Filed: August 21, 2018
    Publication date: November 19, 2020
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. ZON, Joseph MANDELBAUM
  • Patent number: 10835599
    Abstract: The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: November 17, 2020
    Assignees: DUKE UNIVERSITY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Barton F. Haynes, Garnett Kelsoe, Stephen Harrison, Thomas B. Kepler
  • Patent number: 10835486
    Abstract: Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: November 17, 2020
    Assignees: Massachusetts Institute of Technology, The Children's Medical Center Corporation
    Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Arturo Jose Vegas, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup
  • Publication number: 20200345638
    Abstract: Described herein are emulsion compositions comprising fish oil and medium-chain triglycerides (MCT) and/or omega-3 fatty acids and medium-chain triglycerides (MCT). In some embodiments, the compositions further comprise, e.g., alpha-tocopherol, or one or more fatty acids. Further provided herein are methods of using the compositions, e.g., to provide nutrion, e.g., parenteral nutrition to a subject and/or to treat or prevent certain conditions described herein.
    Type: Application
    Filed: August 10, 2018
    Publication date: November 5, 2020
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Mark PUDER, Kathleen Marie GURA
  • Publication number: 20200339636
    Abstract: Provided herein are agents that bind to the lipid binding groove of Frizzled (FZD). In some embodiments, the agent is a fragment of TcdB corresponding to amino acids 1285-1804 of SEQ ID NO: 1. In some embodiments, binding of the agent to the lipid binding groove of FZD inhibits TcdB entry into cells, and/or inhibits Wnt signaling. Methods of treating Clostridium difficile infection (CDI) and methods of treating cancer are also provided.
    Type: Application
    Filed: January 14, 2019
    Publication date: October 29, 2020
    Applicants: Children's Medical Center Corporation, The Regents of the University of California
    Inventors: Min Dong, Liang Tao, Rongsheng Jin, Peng Chen, Aina He
  • Publication number: 20200340033
    Abstract: Provided herein are methods and products for detecting analytes in a sample. The analytes may be rare analytes such as biomarkers in a biological sample. These methods make use of nucleic acid nanoswitches that adopt a particular conformation and have a particular length in the presence of an analyte.
    Type: Application
    Filed: November 20, 2018
    Publication date: October 29, 2020
    Applicant: Children's Medical Center Corporation
    Inventors: Wesley Philip Wong, Johanna Blass, Darren Yang, Clinton H. Hansen
  • Publication number: 20200340058
    Abstract: The present invention features compositions and methods that enhance cell extravasation and/or muscle cell fusion, and methods for identifying genes that enhance or inhibit extravasation and muscle cell fusion. One aspect of the present disclosure provides an isolated cell lacking a gene of Table 1 or expressing a reduced level of a gene of Table 1. In some embodiments, the isolated cell has a CRISPR-edited genome or expresses an inhibitory nucleic acid molecule targeting a gene of Table 1. In some embodiments, this inhibitory nucleic acid molecule is an antisense oligonucleotide molecule, a short interfering RNA (siRNA) molecule, or an small hairpin (shRNA) molecule. Another aspect of the present disclosure provides an isolated cell comprising an expression vector encoding a gene of Table 1.
    Type: Application
    Filed: September 12, 2018
    Publication date: October 29, 2020
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: ANGELA LEK, LOUIS M. KUNKEL, JANELLE M. SPINAZZOLA, YUANFAN ZHANG
  • Publication number: 20200332258
    Abstract: Described herein are methods and compositions for producing modified, PD-L1 expressing hematopoietic stem cells, and uses thereof. Aspects of the invention relate to modulating the expression of micro RNA that controls the expression of PD-L1 in the hematopoietic stem cell. Methods for modulating the expression of micro RNA include, e.g., introducing to the cell a nucleic acid encoding a given micro RNA, or an agent that inhibits a given micro RNA.
    Type: Application
    Filed: September 21, 2018
    Publication date: October 22, 2020
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Paolo FIORINA, Moufida BEN-NASR
  • Patent number: 10806395
    Abstract: Disclosed is a pain detection system and method. Preferred methods include capturing imaging data from patient using functional near-infrared spectroscopy. In methods of the invention, pain may be assessed from a non-responsive patient. Preferred methods may further include measuring hemodynamic parameters using the optical imaging data and averaging the measured hemodynamic parameters to reduce background noise. Additionally, a pattern in the averaged hemodynamic parameters is identified and the pattern is compared to a predetermined associated with patient pain. The method further includes detecting, by the processor, a similarity between the pattern and the predetermined pattern and outputting a signal indicating patient pain.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 20, 2020
    Assignee: Children's Medical Center Corporation
    Inventors: David Borsook, Lino Becerra
  • Patent number: 10806793
    Abstract: Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: October 20, 2020
    Assignee: Children's Medical Center Corporation
    Inventors: Wayne I. Lencer, Daniel J F Chinnapen, Randy Mrsny
  • Patent number: 10799552
    Abstract: Provided are methods for promoting axon regeneration of a Central Nervous System (CNS) neuron and promoting nerve function following injury to a CNS neuron, for example, brain and/or spinal cord injury. Axon regeneration in a CNS neuron or nerve function following injury to a CNS neuron can be promoted by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject suffering from a CNS disorder, wherein a symptom of the CNS disorder is axon degeneration.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: October 13, 2020
    Assignees: Massachusetts Eye and Ear Infirmary, Children's Medical Center Corporation
    Inventors: Demetrios G. Vavvas, Larry Benowitz, Joan W. Miller
  • Publication number: 20200316217
    Abstract: Described herein are engineered ligand that binds a cell surface receptor (e.g., GPCR), with improved affinity, potency, and specificity. By conjugating a sub-optimal ligand for a cell surface receptor (e.g., GPCR) to a targeting molecule that binds an epitope (natural or exogenous epitope) in the extracellular portion of the cell surface receptor (e.g., GPCR), the affinity, potency, and/or specificity of the sub-optimal ligand is enhanced.
    Type: Application
    Filed: March 5, 2020
    Publication date: October 8, 2020
    Applicants: Children's Medical Center Corporation, The General Hospital Corporation
    Inventors: Ross Cheloha, Hidde L. Ploegh, Thomas J. Gardella